The effects of 3-hydroxybutyrate (3-OHB) and hyperosmolarity on glucagon secretion were examined in the isolated perfused canine pancreas. When 3-OHB was infused for 15min into the pancreas perfused with 2.8mM glucose, 5 and 20mM sodium 3-OHB inhibited it after a transient stimuration, whereas a similar transient stimulation was observed also by the infusion of 20mM NaC1 in a control experiment. The above inhibition was not observed under the perfusate condition of 5.5mM glucose plus 10mM arginine. When the isolated canine pancreas was perfused under the perfusate condition of acidosis (pH 7.1), ketoacidosis (pH 7.1 and 20mM 3-OHB) or hyperosmolarity (+60 mOsm/kg with sucrose) throughout the experiment, the glucagon concentrations produced by 2.8mM glucose under the ketoacidotic and hyperosmolar conditions, were less than half of those obtained under the standard condition.
Hyperglucagonemia during diabetic ketoacidosis and non-ketotic hyperosmolar coma in diabetic patients has been well established (Muller et al., 1973; Lindsey et al., 1974) . The major cause of hyperglucagonemia is supposed to be augmented glucagon release provoked by hypovolemia and stress in addition to insulin deficiency and its decreased removal from the kidney (Unger and Orci, 1976) . Although the increase in plasma 3 -hydroxybutylate (3-OHB) is mainly caused by enhanced ketone body production in the liver due to hyperglucagonemia, it has been reported that glucagon release is inhibited by 3-OHB (Edwards and Taylor, 1970) . Namely, hyperketonemia and/or hyperosmolarity produced by hyperglucagonemia might directly influence the glucagon release from 
Materials and Methods
Sodium DL-3-hydroxybutyrate was purchased from the Sigma Chemical Co. (St. Louis , Missouri, USA).
Pancreas perfusion:
The pancreas was isolated from mongrel dogs weighing 14-17kg under pentobarbital anesthesia after an overnight fast. The isolated canine pancreas was perfused by the method of Iversen and Miles (Iversen and Miles, 1971 (Grill and Gerasi, 1976) . After 55 min of perfusion with the above perfusates containing 2.8mM glucose, the increase in the glucose and arginine concentrations was performed by the infusion of glucose and arginine through a side-arm syringe at a rate of 0.2ml/min as shown in Figure 3 . The response of a-cells and n-cells to glucose and arginine added under each perfusate condition was calculated as the area under the curve during each 15 min of infusion ( Figure 4 ).
Hormone assay: Insulin, glucagon and somatostatin were assayed by RIAs, according to the methods of Herbert et al. (Herbert et al., 1965) , Faloona and Unger and Harris et al. (Harris et al., 1978) , respectively, as previously described (Chiba et al., 1985) . The ANOVA with Newman-Keuls procedure for multiple comparisons (Figure 1 , 2) and the Student's t-test for unpaired data were used ( Figure 4 ) for statistical analysis. All data are expressed as mean + SEM and values of P<0.05 were considered to be significant. The glucose and arginine were added to the perfusate as shown in Figure 3 and the cumulative glucagon and insulin outputs during each 15 min period were calculated as described in Materials and Methods. * , P<0.05 vs. control (perfusion with the standard perfusate described in Materials and Methods).
was stimulated as much as that observed under the perfusate condition of 2.8mM
glucose.
Since Na+ directly affects pancreatic hormone secretion (Hales and Milner, 1968; Hermansen, 1980) 20mM NaCl was infused instead of 3-OHB as a control experiment (Figure 2) .
Although a similar pattern of increase in glucagon release to that observed with 3-OHB was obtained with 20mM NaCl, no significant decrease in glucagon was obtained under the perfusate condition with Effects of acidosis, ketoacidosis and hyperosmolarity on glucagon response to glucose and arginine. Figure 3 shows the change in glucagon and insulin levels in the effluent perfusate from the isolated canine pancreas in response to an increase in the glucose and arginine concentrations under the standard perfusate conditions described in Materials and Methods. The same protocol of perfusion was employed under the conditions of acidosis (pH 7.1), ketoacidosis (20mM 3-OHB, pH 7.1) and hyperosmolarity (+60 mOsm/kg).
The glucagon release during each 15min period was calculated in each perfusate condition (Figure 4-A) . Ketoacidosis suppressed the glucagon release induced by glucopenia (2.8mM glucose). Hyperosmolarity suppressed glucagon release induced by both glucopenia (2.8mM glucose) and arginine (22mM glucose plus 10mM arginine).
The insulin release was not inhibited significantly under these conditions (Figure  4-B) . The insulin release suppressed by glucopenia was restored under the ketoacidotic condition.
Discussion
The present study demonstrates that 1) 3-OHB suppresses glucagon release stimulated by glucopenia (2.8mM glucose) in both short term and long term experiments ( Figure  1 and 4-A) and slightly augments it stimulated by arginine ( Figure  1) ; 2) The rapid and transient increase in glucagon release brought about by sodium 3-OHB with 2.8mM glucose is ascribed to the effect of Na+ in the sodium 3-OHB solution ( Figure 2) ; and 3) Hyperosmolarity inhibits the glucagon release stimulated by both glucopenia and arginine (Figure 4-A) .
Concerning the insulin and somatostatin release, stimulatory effects similar to the present results have been reported (Malaisse and Malaisse-Lagae, 1968; Goberna et al., 1974 , Hermansen, 1982 .
The present study demonstrates that 3-OHB stimulates the insulin and somatostatin release even under the low glucose condition.
Concerning the glucagon release, Edwards and Taylor reported that 10mM DL-3-OHB suppressed glucagon release from the isolated islets of guinea-pigs incubated in a medium containing 5.5mM glucose (Edwards and Taylor, 1970) , which is consistent with the present results.
In the experiment to elicit the long term effects of ketoacidosis, the ketoacidotic perfusate inhibited glucagon release stimulated by glucopenia (2.8mM glucose) and tended to inhibit it under the perfusate condition of 12.5mM and 22mM glucose, whereas it did not affect glucagon release under the perfusate condition of 22 mM glucose plus 10mM arginine ( Figure  4 -A). The insulin release was not inhibited by this perfusion (Figure 4-B) , suggesting that the inhibitory effect cannot be ascribed to its non-specific toxic effect on islet cells. On the other hand, it has been reported that the 3-OHB infusion in vivo does not have a clear effect on basal and hypoglycemia stimulated glucagon secretion in normal men and dogs (Sherwin et al., 1975; Muller et al., 1976; Quabbe et al., 1983) . Namely, Quabbe et al. demonstrated that the infusion of 3-011B alone (resultant plasma 3-OHB concentration was about 1mM) caused a slight increase in basal plasma glucagon (10-20pg/ml) and a delayed peak of plasma glucagon in response to insulin-hypoglycemia.
These discrepancies might be ascribed to an offsetting action between the slight inhibitory effect of 3-OHB on glucagon secretion produced by glucopenia and its small stimulatory effect on glucagon secretion produced by arginine, in addition to the difference between in vitro and in vivo experiments and/or the difference in the 3-OHB concentration used. The above results were obtained with glucagon, in terms of its ketone body production, due to aging (Okuda et al., 1987) .
